1P-AL-LAD
1P-AL-LAD is a proposed 1-propionyl prodrug of AL-LAD (6-allyl-nor-LSD), combining the N1-propionyl modification of 1P-LSD with the allyl-substituted lysergamide AL-LAD. It is an extremely obscure research lysergamide with negligible human data.
01 Overview
1P-AL-LAD applies the same N1-acyl 'legal-lysergamide' strategy seen in 1P-LSD to AL-LAD, the intent being an in-vivo conversion to AL-LAD. It has appeared only fleetingly in research-chemical discussion and lacks meaningful characterisation.
Assuming prodrug conversion, effects would resemble AL-LAD: a somewhat shorter, more visual, less anxious LSD-like experience. All of this is inference from related compounds rather than direct data.
02 Mechanism
Presumed prodrug hydrolysing to AL-LAD, a 5-HT2A partial agonist lysergamide; the N1-propionyl group is expected to be cleaved in vivo.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Estimated | 100–200 µg | Sublingual | Extrapolated from AL-LAD/1P-LSD; not established. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Visual psychedeliaPresumed AL-LAD-like colourful visuals, inferred not observed. | moderate-strong | Unconfirmed | |
| Lower anxiety than LSDAL-LAD is often described as less anxiogenic than LSD; assumed to carry over. | uncertain | Unconfirmed |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| VasoconstrictionLysergamides cause mild-moderate vasoconstriction; expected here. | Moderate | Unknown | Unconfirmed | |
| Unknown prodrug behaviourWhether and how completely it converts to AL-LAD in humans is unverified. | Moderate | Unknown | Unconfirmed |